Oxidative Stress and Neuroprotection

- Metal Specificity of an iron-responsive element in Alzheimer's APP mRNA 5' untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazin chelator

- Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection

- Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo

- Acute and chronic affects of developmental iron deficiency on mRNA expression patterns in the brain

- A new look at levodopa based on the ELLDOPA study

- Altered regulation of iron transport and storage in Parkinson's disease

- The relationship of early studies of monoamine oxidase to present concepts

- Neuroprotection for Parkinson's disease

- Deprenyl: from chemical synthesis to neuroprotection

- Green tea catechins as brain-permeable, non toxic iron chelators to "iron out iron" from the brain

- Isatin interaction with glyceraldehyde-3-phosphate dehydrogenase, a putative target of neuroprotective drugs: partial agonism with deprenyl

- Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson's disease induced by the Japanese encephalitis virus

- The DONPAD-study - treatment of dementia in patients with Parkinson's disease with donepezil

- Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells

- Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling to cell death or neuroprotection

- Inhibition of amine oxidises by the histamine-1 receptor antagonist hydroxyzine

- Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy

- Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole

- The use of rasagiline in Parkinson's disease

- Apoptosis inhibition in T cells triggers the expression of proinflammatory